| Objective:The aim of this study was to compare efficacy and safety between the treatment of transarterial chemoembolization(TACE)combined with apatinib and TACE alone in the hepatocellular carcinoma(HCC)patients accompanied with portal vein tumor thrombus(PVTT).Methods:60 HCC patients with portal vein tumor thrombus(PVTT)receiving TACE with apatinib or TACE alone were consecutively recruited in this retrospective cohort study.Treatment response was assessed at month.Overall survival were calculated.Adverse events occurred during treatment were recorded.Results:60 cases were selected,as of closed follow-up,no cases were missed,of which 6 patients were still alive(as of December 2018 at the end of the follow-up),there were 5 people in the experimental group and 1 in the control group.1.Efficacy in the third month: The objective remission rate in the experimental group was 40%,the disease Control rate(DCR)was 80%,and the objective remission rate in the control group was 13.33%(ORR),Disease Control rate(DCR)was 63.33%.The objective remission rate(ORR)of the two groups was statistically significant(P=0.020<0.05),and the disease control rates of the two groups were not statistically significant(P=0.152>0.05).2.Used Kaplan-meier method for survival analysis,Log-rank test for comparison,the results show that The median OS in the experimental group and the control group was 8 months and 6 months,respectively,and the difference was statistically significant(P<0.05).3.The difference between the two groups of adverse reactions were mainly hypertension,proteinuria,hand and foot syndrome,oral ulcer,P value <0.05,although there were differences,but could be tolerated.Conclusion:TACE combined with Apatinib in the treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis can obtain better short-term curative effect and total survival time,adverse reactions can be tolerated. |
PDF Full Text Request